During June, investigators reported new data that has advanced the treatment landscape for lung cancer, including new FDA ...

Access to and affordability of immune checkpoint inhibitors, which can be lifesaving if patients receive them on time and ...

The anti-GPC3 targeted therapies market is expected to witness growth in the coming years, driven by the increasing incidence of cancer cases, clinical pipeline activity, and anticipated regulatory ...

Recent oncology breakthroughs showcase innovative treatments and approvals, enhancing patient outcomes in CLL, RCC, NSCLC, ...

A new research paper was published in Volume 16 of Oncotarget on June 17, 2025, titled "Molecular landscape of HER2-mutated ...

Our findings highlight the molecular diversity and diagnostic challenges of HER2-mutated NSCLC in underrepresented ...

While U.S. cancer death rates continue to decline, global cancer cases are expected to rise sharply. As well, early-onset diagnoses in younger patients are climbing at a troubling pace . Now, industry ...

Cancer is not a welcome diagnosis, but breakthroughs in genetic sequencing and immunotherapy are making some cancers easier ...

Panelists discuss how comprehensive patient education about expected adverse effects, combined with prophylactic measures ...

Despite advances in drug development, some patients with non-small-cell lung cancer (NSCLC) have suboptimal responses to treatment.